Ascendis Pharma A/S $ASND Position Increased by Toth Financial Advisory Corp

Toth Financial Advisory Corp raised its stake in Ascendis Pharma A/S (NASDAQ:ASND) by 679.8% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 4,640 shares of the biotechnology company’s stock after buying an additional 4,045 shares during the quarter. Toth Financial Advisory Corp’s holdings in Ascendis Pharma A/S were worth $989,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently modified their holdings of ASND. Avoro Capital Advisors LLC boosted its stake in Ascendis Pharma A/S by 2.6% during the 3rd quarter. Avoro Capital Advisors LLC now owns 5,110,000 shares of the biotechnology company’s stock valued at $1,015,919,000 after purchasing an additional 130,000 shares during the period. Capital International Investors raised its stake in Ascendis Pharma A/S by 0.4% during the 3rd quarter. Capital International Investors now owns 3,060,616 shares of the biotechnology company’s stock valued at $608,481,000 after acquiring an additional 13,685 shares in the last quarter. Wellington Management Group LLP boosted its position in Ascendis Pharma A/S by 95.9% during the 3rd quarter. Wellington Management Group LLP now owns 1,798,931 shares of the biotechnology company’s stock worth $357,645,000 after acquiring an additional 880,836 shares during the period. Perceptive Advisors LLC acquired a new position in Ascendis Pharma A/S during the 2nd quarter worth $166,367,000. Finally, Principal Financial Group Inc. grew its stake in shares of Ascendis Pharma A/S by 2,722.9% in the third quarter. Principal Financial Group Inc. now owns 793,677 shares of the biotechnology company’s stock worth $157,791,000 after purchasing an additional 765,561 shares in the last quarter.

Analyst Ratings Changes

A number of research analysts recently commented on the stock. Wolfe Research reiterated an “outperform” rating and set a $260.00 price objective on shares of Ascendis Pharma A/S in a research note on Monday, March 2nd. Morgan Stanley restated an “overweight” rating and issued a $256.00 target price on shares of Ascendis Pharma A/S in a research report on Thursday, February 12th. Royal Bank Of Canada increased their price target on Ascendis Pharma A/S from $250.00 to $275.00 and gave the company an “outperform” rating in a research note on Monday, March 2nd. Bank of America reiterated a “buy” rating and set a $262.00 price target on shares of Ascendis Pharma A/S in a research report on Thursday, March 5th. Finally, The Goldman Sachs Group reissued a “buy” rating and issued a $255.00 price objective on shares of Ascendis Pharma A/S in a research note on Monday, March 2nd. One investment analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $289.89.

Ascendis Pharma A/S Price Performance

ASND stock opened at $229.25 on Friday. Ascendis Pharma A/S has a 52-week low of $124.06 and a 52-week high of $248.60. The company’s 50 day simple moving average is $227.16 and its 200-day simple moving average is $213.91. The firm has a market capitalization of $14.29 billion, a P/E ratio of -52.10 and a beta of 0.49.

Ascendis Pharma A/S (NASDAQ:ASND) last released its earnings results on Thursday, February 12th. The biotechnology company reported ($0.64) earnings per share for the quarter, missing the consensus estimate of ($0.06) by ($0.58). The business had revenue of $290.38 million during the quarter, compared to the consensus estimate of $285.35 million. Sell-side analysts predict that Ascendis Pharma A/S will post -4.34 EPS for the current fiscal year.

About Ascendis Pharma A/S

Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company’s lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S.